Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Quarterly Results For The Quarter ....
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 31 Jul 2026, 12:40 PM IST · BSE ID: 8a710f96-2543-4e26-899d-645cdacfc552
View Original BSE Filing (PDF)
💡
In Simple Terms
Marksans Pharma will hold a board meeting on August 12, 2026, to review and approve its latest quarterly financial results.
🤖 AI Summary
- Marksans Pharma Board Meeting on August 12, 2026, to approve Q1 FY27 Unaudited Financial Results.
- Meeting will consider both Standalone and Consolidated financial results for June 30, 2026 quarter.
- Trading window for designated persons closed from July 1, 2026, due to financial results consideration.
- Trading window closure extends up to August 14, 2026, 48 hours post results announcement.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this intimation of a board meeting.
👤
Who Is Affected
All shareholders are indirectly affected as the company prepares to disclose its Q1 FY27 financial performance. However, there is no direct impact on shareholding or rights from this announcement.
🔍
Management Signal
Management is adhering to regulatory requirements by intimating the board meeting for financial results approval and implementing insider trading window closure.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Marksans Pharma's Q1 FY27 Unaudited Financial Results announcement on August 12, 2026.
Review standalone and consolidated revenue for Q1 FY27.
Assess profit after tax for the quarter ended June 30, 2026.
LOW RISK
This is a standard procedural announcement with no inherent risks identified within the filing content.
💡 Investor Takeaway
Marksans Pharma has scheduled a Board Meeting for August 12, 2026, to approve its Unaudited Financial Results for the quarter ended June 30, 2026. The trading window for designated persons is closed from July 1, 2026, to August 14, 2026.
📅 Company Track Record
Marksans Pharma refiled its audited FY26 results on June 26, 2026, confirming a Profit After Tax of 3,006.98 million. On May 26, 2026, the company reported its audited FY26 results and proposed a final dividend of Rs. 0.90 per share.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
When is Marksans Pharma's Board Meeting scheduled?
Marksans Pharma's Board of Directors meeting is scheduled for Wednesday, August 12, 2026.
What is the primary agenda of Marksans Pharma's upcoming Board Meeting?
The primary agenda is to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) for the Quarter ended June 30, 2026.
When is the trading window closed for Marksans Pharma's Designated Persons?
The trading window for Marksans Pharma's Designated Persons (including Directors) and their immediate relatives has been closed from July 1, 2026, and will remain closed until August 14, 2026 (both days inclusive).
Questions based on this BSE filing only. For information purposes.